Skip to main content
Glama

Resolve Entity

resolve_entity
Read-onlyIdempotent

"What's the ticker for…" / "find the CIK for…" / "what's the LEI for…" / "what's the RxCUI for…" / "look up the ID for…" / "what is X's official identifier" / "who owns X" / "is X a subsidiary of Y" — resolve a user-spoken NAME to the canonical/official identifiers other tools require as input. Use FIRST whenever you have a name but need an ID. SUPPORTED TYPES: "company" (cross-source identity spine: 10-digit CIK + ticker + company_name from SEC EDGAR, legal-entity LEI from GLEIF with parent/ultimate-parent/children ownership when the LEI resolves, and security FIGI from OpenFIGI — by exact ticker map when a ticker is implied, and otherwise by name search, so NON-EQUITY instruments that never have a ticker (municipal and corporate bonds, notes, authority debt) DO resolve here; when a name matches more than one instrument it asserts nothing and returns figi_candidates to pick from, which is the correct answer to an issuer name that does not identify a single bond; every identifier is labelled with the source that established it, and an identifier that could NOT be resolved is stated explicitly under unresolved rather than omitted — accepts ticker, CIK, ISIN, or company name as input; an ISIN like "CH0038863350" resolves to the LEGAL ENTITY that issued the security via the GLEIF ISIN-to-LEI mapping, covering non-US issuers EDGAR cannot reach), "drug" (returns RxCUI + ingredient + brand from RxNorm + pipeworx://rxnorm/concept/{rxcui} citation; accepts brand or generic name). LEI/FIGI enrichment degrades gracefully — if GLEIF or OpenFIGI is unavailable, the EDGAR identifiers still return. Each call cascades through several lookup endpoints internally — using resolve_entity replaces 2-3 manual lookups.

Input Schema

TableJSON Schema
NameRequiredDescriptionDefault
typeYesEntity type: "company" or "drug".
valueYesFor company: ticker (AAPL), CIK (0000320193), or name. For drug: brand or generic name (e.g., "ozempic", "metformin"). Pass the ENTITY NAME ONLY — for a bond that is the ISSUER exactly as printed ("NEW YORK ST DORM AUTH"), never the question's full noun phrase ("NEW YORK ST DORM AUTH revenue bonds"): the FIGI lookup matches instrument names, so trailing security-class words match nothing.

Schema Changelog

Changes observed during successful MCP inspections. Dates show when Glama detected each change.

  1. Changed1 schema field changed
    • changedInput schema / properties / value / description
      Previous value: -"For company: ticker (AAPL), CIK (0000320193), or name. For drug: brand or generic name (e.g., \"ozempic\", \"metformin\")."New value: +"For company: ticker (AAPL), CIK (0000320193), or name. For drug: brand or generic name (e.g., \"ozempic\", \"metformin\"). Pass the ENTITY NAME ONLY — for a bond that is the ISSUER exactly as printed (\"NEW YORK ST DORM AUTH\"), never the question's full noun phrase (\"NEW YORK ST DORM AUTH revenue bonds\"): the FIGI lookup matches instrument names, so trailing security-class words match nothing."
  2. First observed

TDQS

A4.7/5.0
Behavior5/5

Does the description disclose side effects, auth requirements, rate limits, or destructive behavior?

Beyond the readOnly/openWorld/idempotent annotations, the description discloses multiple important behaviors: graceful degradation when GLEIF/OpenFIGI are unavailable, explicit `unresolved` output instead of omission, `figi_candidates` when a name is ambiguous, source-labelling of identifiers, and the ISIN-to-LEI mapping behavior. This is substantially more than the annotations alone convey.

Agents need to know what a tool does to the world before calling it. Descriptions should go beyond structured annotations to explain consequences.

Conciseness4/5

Is the description appropriately sized, front-loaded, and free of redundancy?

The description is dense and front-loaded with example queries and the 'Use FIRST' directive. The long parenthetical about company resolution is heavy but packs necessary nuance about EDGAR, GLEIF, OpenFIGI, and ambiguity handling. It earns its length for a complex tool, though a bit more paragraphing would improve scanability.

Shorter descriptions cost fewer tokens and are easier for agents to parse. Every sentence should earn its place.

Completeness5/5

Given the tool's complexity, does the description cover enough for an agent to succeed on first attempt?

Despite having no output schema, the description explains what the agent can expect back: resolved identifiers, source labels, `unresolved` fields, `figi_candidates`, RxCUI citations, and graceful degradation. It covers input acceptance, edge cases (ambiguous names, non-US issuers, non-ticker instruments), and fallback behavior — complete for an agent to call and interpret correctly.

Complex tools with many parameters or behaviors need more documentation. Simple tools need less. This dimension scales expectations accordingly.

Parameters5/5

Does the description clarify parameter syntax, constraints, interactions, or defaults beyond what the schema provides?

The schema already covers the two parameters 100%, so baseline is 3, but the description adds high-value semantics: the exact meaning of `value` for companies versus drugs, the instruction to pass the entity name only (with a bond issuer example and a common mistake), and how different input ID types map to different resolution paths. This goes well beyond the schema.

Input schemas describe structure but not intent. Descriptions should explain non-obvious parameter relationships and valid value ranges.

Purpose5/5

Does the description clearly state what the tool does and how it differs from similar tools?

The description names a specific action — resolving a user-spoken NAME to canonical/official identifiers — and supports it with concrete example queries. It goes beyond the title by framing the tool's role as a gateway to identifiers other tools require, and it clearly separates from siblings like entity_profile by emphasizing the 'name-to-ID' use case.

Agents choose between tools based on descriptions. A clear purpose with a specific verb and resource helps agents select the right tool.

Usage Guidelines4/5

Does the description explain when to use this tool, when not to, or what alternatives exist?

It gives explicit guidance: 'Use FIRST whenever you have a name but need an ID.' It also details supported entity types and input formats. It does not explicitly exclude cases where other sibling tools would be preferred, but the 'FIRST' directive and the 'other tools require as input' framing effectively route the agent to it.

Agents often have multiple tools that could apply. Explicit usage guidance like "use X instead of Y when Z" prevents misuse.

Try in Browser

Glama MCP Gateway

Add one secure layer between your agents and this server.

TDQS

B3.3/5.0
Disambiguation2/5

Many tools have overlapping functionality, such as ask_pipeworx, ask_pipeworx_beta, and ask_pipeworx_grounded, which are essentially the same with minor differences. The polymarket_* family also has five tools with similar names and purposes, making it easy to select the wrong one despite detailed descriptions.

Naming Consistency2/5

Tool names mix verb-first patterns (ask, generate, list, remember) with noun-first patterns (entity_profile, polymarket_arbitrage), and include camelCase like ai_visibility_check. This inconsistent naming style makes the set feel arbitrary and harder to navigate.

Tool Count3/5

With 36 tools, the server exceeds the typical well-scoped range of 3-15. While the multi-purpose nature justifies a larger set, the presence of many near-duplicates (beta/grounded variants, multiple polymarket tools) inflates the count without proportional functional gain.

Completeness4/5

The toolset covers a wide array of domains including translation, entity resolution, financial data, prediction markets, memory, subscriptions, and AI visibility. It appears very comprehensive for its intended multi-purpose server, with no obvious major gaps in core capabilities.